Lucid Diagnostics Inc
NASDAQ:LUCD
| Market Cap (Intraday) | 49.71M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.27 |
| 50-Day MA | $1.59 |
| 200-Day MA | $2.06 |
Lucid Diagnostics Inc Stock, NASDAQ:LUCD
One Grand Central Place, 60 East 42nd Street, New York, New York 10165
United States of America
Phone: +1.212.949.4319
Number of Employees:
Description
Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.